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[Background/Aims] Cytopenia during interferon-based (IFN-based) therapy for chronic 
hepatitis C (CHC) often necessitates reduction of doses of drugs and premature 
withdrawal from therapy resulting in poor response to treatment. To identify genetic 
variants associated with IFN-induced neutropenia, we conducted a genome-wide 
association study (GWAS) in 416 Japanese CHC patients receiving IFN-based therapy. 
[Methods] Based on the results, we selected 192 candidate single nucleotide 
polymorphisms (SNPs) to carry out a replication analysis in an independent set of 404 
subjects. [Results] The SNP rs2305482, located in the intron region of the PSMD3 gene 
on chromosome 17, showed a strong association when the results of GWAS and the 
replication stage were combined (OR = 2.18, P = 3.05  10-7 in the allele frequency 
model). Logistic regression analysis showed that rs2305482 CC and neutrophil count at 
baseline were independent predictive factors for IFN-induced neutropenia (OR = 2.497, 
P = 0.0072 and OR = 0.998, P <0.0001, respectively). Furthermore, rs2305482 genotype 
was associated with the doses of pegylated interferon (PEG-IFN) that could be tolerated 
in hepatitis C virus genotype 1-infected patients treated with PEG-IFN plus ribavirin, 
but not with treatment efficacy. [Conclusion]Our results suggest that genetic testing for 
this variant might be useful for establishing personalized drug dosing in order to 
minimize drug-induced adverse events. 
